World News

New Orleans-based Revolo Biotherapeutics Activates Clinical Trial and Commences Enrollment in Phase 2 Clinical Study of ‘1104 in Allergic Disease in the UK

  NEW ORLEANS/LONDON (press release) – New Orleans-based Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that a…